Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.

Chang H, Shin SK, Cho BC, Lee CG, Kim CB, Kim DJ, Lee JG, Hur J, Lee CY, Bae MK, Kim HR, Lee SK, Park JC, Lee H, Kim HI, Chung H, Cha J, Lee YC, Kim JH.

Cancer Chemother Pharmacol. 2014 Apr;73(4):665-71. doi: 10.1007/s00280-013-2371-y. Epub 2014 Feb 22.

PMID:
24562525
2.

Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.

Iwase H, Shimada M, Tsuzuki T, Hirashima N, Okeya M, Hibino Y, Ryuge N, Yokoi M, Kida Y, Kuno T, Tanaka Y, Kato B, Esaki M, Urata N, Kato E.

Oncology. 2013;84(6):342-9. doi: 10.1159/000348383. Epub 2013 May 14.

PMID:
23689040
3.

[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].

Iwase H.

Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:224-9. Japanese.

PMID:
16898007
4.

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).

Tahara M, Fuse N, Mizusawa J, Sato A, Nihei K, Kanato K, Kato K, Yamazaki K, Muro K, Takaishi H, Boku N, Ohtsu A.

Cancer Sci. 2015 Oct;106(10):1414-20. doi: 10.1111/cas.12764. Epub 2015 Sep 21.

5.

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.

Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1484-93.

PMID:
15590179
6.

Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.

Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, Tanaka M, Hironaka S, Hashimoto T, Ura T, Kodaira T, Yoshimura K.

Jpn J Clin Oncol. 2013 Jun;43(6):608-15. doi: 10.1093/jjco/hyt048. Epub 2013 Apr 12.

PMID:
23585687
7.

Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.

Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, Hajiro K, Matsusue S, Takeda H.

Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1049-59.

PMID:
9539559
8.

Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.

Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):328-34.

PMID:
12738305
9.

A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.

Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1967-72. doi: 10.1016/j.ijrobp.2011.01.043. Epub 2011 Apr 18.

10.

A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.

Shim HJ, Kim KR, Hwang JE, Bae WK, Ryu SY, Park YK, Nam TK, Chung IJ, Cho SH.

Cancer Chemother Pharmacol. 2016 Mar;77(3):605-12. doi: 10.1007/s00280-016-2973-2. Epub 2016 Feb 5.

PMID:
26846507
11.

Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.

Yamashita H, Haga A, Takenaka R, Kiritoshi T, Okuma K, Ohtomo K, Nakagawa K.

Radiat Oncol. 2016 Jan 19;11:4. doi: 10.1186/s13014-016-0587-9.

12.

Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takiuchi H, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG).

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033. Epub 2010 Oct 6.

PMID:
20932658
13.

Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N.

Lung Cancer. 2013 Dec;82(3):449-54. doi: 10.1016/j.lungcan.2013.09.004. Epub 2013 Sep 19.

PMID:
24099666
14.

Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer.

Kim JH, Choi EK, Kim SB, Park SI, Kim DK, Song HY, Jung HY, Min YI.

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):1-12.

PMID:
11316540
15.

A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer.

Kawaguchi T, Takada M, Ando M, Okishio K, Atagi S, Fujita Y, Tomizawa Y, Hayashihara K, Okano Y, Takahashi F, Saito R, Matsumura A, Tamura A.

Eur J Cancer. 2012 Mar;48(5):672-7. doi: 10.1016/j.ejca.2011.11.020. Epub 2011 Dec 13.

PMID:
22172569
16.

Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.

Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9.

PMID:
12007951
17.
18.

Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36.

PMID:
15380576
19.

Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.

Choi N, Park SD, Lynch T, Wright C, Ancukiewicz M, Wain J, Donahue D, Mathisen D.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):111-22.

PMID:
15337546
20.

Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.

Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):120-7.

PMID:
12909224

Supplemental Content

Support Center